Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eureka CD19 ARTEMIS T-cell therapy
- Development stage
- Unknown
- Lead developer
- Eureka Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Eureka CD19 ARTEMIS T-cell therapy is an investigational autologous T-cell therapy developed by Eureka Therapeutics using its proprietary ARTEMIS platform. While CD19 is a well-established target for B-cell malignancies, this specific program targets multiple solid tumors through a strategic partnership with Imugene. The therapeutic approach utilizes Imugene's onCARlytics (CF33-CD19) oncolytic virus to infect tumor cells and induce the surface expression of CD19, a process termed 'marking' the tumor. The CD19-targeted ARTEMIS T-cells then recognize and eliminate these newly CD19-positive solid tumor cells. The ARTEMIS platform is engineered to mimic the natural T-cell receptor (TCR) complex, potentially offering improved safety and efficacy profiles, including reduced cytokine release syndrome (CRS) risk, compared to conventional CAR-T therapies.
- Other names
- CD19 T CellsCD-19 T CellsCD 19 T CellsEureka CD19 T-cell therapy
02
Targets
Beyond the preview
Go deeper on Eureka CD19 ARTEMIS T-cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eureka CD19 ARTEMIS T-cell therapy.